NTAGI to discuss allowing Biological Corbevax as booster for Covishield, Covaxin recipients
CORBEVAX is a protein sub-unit vaccine, developed from a component of the spike protein on the virus's surface, which helps the body build the immune response against the virus.
New Delhi: Allowing Biological E's Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet today, sources said. The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. CORBEVAX is a protein sub-unit vaccine,...
Login or Register to read the full article
New Delhi: Allowing Biological E's Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet today, sources said.
The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above.
CORBEVAX is a protein sub-unit vaccine, developed from a component of the spike protein on the virus's surface, which helps the body build the immune response against the virus. The vaccine has the Receptor Binding Domain (RBD) protein as an antigen, CpG 1018 and Aluminium hydroxide as adjuvants formulated in Tris buffer. Corbevax is currently being used to inoculate children in the age group of 12 to 14 years.
"The National Technical Advisory Group on Immunisation (NTAGI) will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated with Covishield or Covaxin," a source told PTI.
The government advisory panel is also expected to review the trial data of the country's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute of India.
A separate HPV working group of the NTAGI had, on June 8, examined the vaccine's clinical trial data and usefulness for inclusion in the national immunisation programme, sources had said.
The recommendation of the Standing Technical Sub-Committee (STSC) of the NTAGI on reducing the gap between the second dose and the precaution dose of Covid vaccines from nine to six months may also be ratified at the meeting to be chaired by the Union health secretary.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd